Continued Angiogenesis Suppression Following Progression on Bevacizumab in mCRC

June 18, 2014
Paulo Marcelo Hoff, MD, PhD, FACP

Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses continued angiogenesis suppression following progression on bevacizumab in metastatic colorectal cancer (mCRC).

Clinical Pearls

Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses continued angiogenesis suppression following progression on bevacizumab in metastatic colorectal cancer (mCRC). This study, which analyzes the consistency of effect of ziv-aflibercept in the bevacizumab pre-treated subgroup of patients in the VELOUR trial stratified by first-line progression ≥ 9 months versus < 9 months, was presented at the 2014 ASCO Annual Meeting.

  • In mCRC, it is beneficial to continue to suppress angiogenesis after first progression, except in patients who had progressed rapidly on first-line therapy.
  • Researchers set out to determine if the efficacy of the anti-angiogenic agent ziv-aflibercept was affected by the timing of progression on first-line therapy.
  • At the start of the trial, 9 months was considered to be a reasonable cutoff between early and late progression.

<<<

View more from the 2014 ASCO Annual Meeting